T. Rowe Price Associates
TERN

T. Rowe Price Associates’s Terns Pharmaceuticals TERN Stock Holding History

T. Rowe Price Associates’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.5M Sell
634,496
-339,816
-35% -$14M ﹤0.01% 899
2025
Q4 		$39.4M Buy
974,312
+880,139
+935% +$20.3M ﹤0.01% 880
2025
Q3 		$708K Buy
94,173
+14,605
+18% +$93.3K ﹤0.01% 2222
2025
Q2 		$297K Buy
79,568
+3,516
+5% +$11K ﹤0.01% 2537
2025
Q1 		$210K Sell
76,052
-1,428,186
-95% -$5.83M ﹤0.01% 2612
2024
Q4 		$8.34M Buy
1,504,238
+28,559
+2% +$193K ﹤0.01% 1182
2024
Q3 		$12.3M Buy
1,475,679
+1,448,996
+5,430% +$11.9M ﹤0.01% 1104
2024
Q2 		$182K Buy
26,683
+5,989
+29% +$36.3K ﹤0.01% 2613
2024
Q1 		$136K Buy
20,694
+2,261
+12% +$14.8K ﹤0.01% 2719
2023
Q4 		$120K Buy
18,433
+647
+4% +$3.42K ﹤0.01% 2688
2023
Q3 		$90K Buy
17,786
+800
+5% +$5.08K ﹤0.01% 2688
2023
Q2 		$149K Buy
+16,986
New +$198K ﹤0.01% 2608

Other funds holding TERN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

T. Rowe Price Associates's TERN Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Terns Pharmaceuticals (TERN) stake by 35% in Q1 2026, selling an estimated $14M and leaving 634,496 shares worth $33.5M. The position accounts for ﹤0.01% of the portfolio, ranked #899.

T. Rowe Price Associates first reported a position in TERN in Q2 2023 and has held it in 12 quarters since. The position peaked at $39.4M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • T. Rowe Price Associates held 634,496 shares of Terns Pharmaceuticals worth $33.5M as of Q1 2026.
  • T. Rowe Price Associates sold 339,816 Terns Pharmaceuticals shares in Q1 2026, an estimated $14M.
  • Terns Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #899 holding.
  • T. Rowe Price Associates first reported a position in Terns Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • T. Rowe Price Associates's Terns Pharmaceuticals position peaked at $39.4M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.